表紙:個別化医療におけるAIの機会
市場調査レポート
商品コード
1759018

個別化医療におけるAIの機会

AI Opportunities in Personalised Medicine


出版日
ページ情報
英文
納期
即日から翌営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.64円
個別化医療におけるAIの機会
出版日: 2025年06月30日
発行: FirstWord Group
ページ情報: 英文
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、個別化医療におけるAIの機会について調査し、AIを活用した技術が医薬品開発におけるリスクをどのように軽減し、患者の層別化を強化し、医療の個別化を促進しているかを詳細に分析しています。また、医療を個別化するためにAIを展開した実際の使用事例や教訓を紹介しています。

主な内容

  • 1. AIが個別化医療の開発に与えた影響
  • 2. AIを活用した技術は、医薬品開発と個別化におけるリスクをどのような方法で軽減したか
  • 3. 標的同定と個別化医療の開発において、人間の能力を高めるためにAIを活用する際の主な課題
  • 4. 医療の個別化を改良するためにAIがどのように展開され、どのような教訓が得られたか
  • 5. 精密医療の市場参入と償還を強化するためのAIの活用に向けた主要動向と将来の機会
  • 6. バイオ製薬企業は、個別化医療構想にAIを効果的に統合するために、データのハードルをどのように克服できるか

主要企業

  • AbbVie
  • AI Proteins
  • Aitia
  • AstralBio
  • AstraZeneca
  • Bayer
  • BigHat Biosciences
  • Boehringer Ingelheim
  • Brightseed
  • Bristol Myers Squibb
  • Carebot
  • Caris Life Sciences
  • Certis Oncology Solutions
  • Charles River Laboratories
  • Click Therapeutics
  • ConcertAI
  • Dyno Therapeutics
  • Eko Health
  • Eli Lilly
  • Formation Bio
  • Genentech
  • Genesis Therapeutics
  • Gilead
  • Google
  • Google DeepMind
  • GS
  • K Haleon
  • Harbour BioMed
  • Iambic Therapeutics
  • iBio
  • Immunai
  • Incyte
  • Inimmune
  • Insilico Medicine
  • invoX Pharma
  • Johnson & Johnson
  • Lundbeck
  • Menarini
  • Merck & Co.
  • Microsoft
  • Moderna
  • Novartis
  • Novo Nordisk
  • Nvidia
  • OpenAI
  • Optellum
  • Otsuka
  • Owkin
  • Paige.AI
  • Path AI
  • Pathos
  • Pfizer
  • Qureight
  • Rad AI
  • Rein Therapeutics
  • Roche
  • Sanofi
  • Servier
  • Snowflake
  • Takeda
  • Tempus
  • Tenacia Biotechnology
  • Tevogen Bio
  • Therasid Bioscience
  • Valo Health
  • Variational AI
目次

This report explores the transformative role of artificial intelligence in personalised medicine, focusing on its application in drug discovery and clinical decision making. It provides an in-depth analysis of how AI-enabled technologies are mitigating risks in drug development, enhancing patient stratification and facilitating the personalisation of care. The report also highlights real-world use cases and lessons learned from deploying AI to personalise medical care, offering a comprehensive overview for biopharma professionals looking to navigate the evolving landscape of AI-driven healthcare solutions.

Gain insights into the significant impact of AI on the development of personalised therapies, the key challenges in integrating AI with human capabilities and the future opportunities for biopharma to leverage AI in improving market access and reimbursement strategies.

Key Questions Answered:

  • 1. How has AI significantly impacted the development of personalised medicines?
  • 2. In what ways have AI-enabled technologies mitigated risks in drug development and personalisation?
  • 3. What are the key challenges in utilising AI to enhance human capabilities in target identification and personalised medicine development?
  • 4. How has AI been deployed to improve the personalisation of care, and what lessons have been learned?
  • 5. What are the key trends and future opportunities for leveraging AI to enhance market access and reimbursement of precision medicine?
  • 6. How can biopharma companies overcome data hurdles to effectively integrate AI in personalised medicine initiatives?

Key Companies:

  • AbbVie
  • AI Proteins
  • Aitia
  • AstralBio
  • AstraZeneca
  • Bayer
  • BigHat Biosciences
  • Boehringer Ingelheim
  • Brightseed
  • Bristol Myers Squibb
  • Carebot
  • Caris Life Sciences
  • Certis Oncology Solutions
  • Charles River Laboratories
  • Click Therapeutics
  • ConcertAI
  • Dyno Therapeutics
  • Eko Health
  • Eli Lilly
  • Formation Bio
  • Genentech
  • Genesis Therapeutics
  • Gilead
  • Google
  • Google DeepMind
  • GS
  • K Haleon
  • Harbour BioMed
  • Iambic Therapeutics
  • iBio
  • Immunai
  • Incyte
  • Inimmune
  • Insilico Medicine
  • invoX Pharma
  • Johnson & Johnson
  • Lundbeck
  • Menarini
  • Merck & Co.
  • Microsoft
  • Moderna
  • Novartis
  • Novo Nordisk
  • Nvidia
  • OpenAI
  • Optellum
  • Otsuka
  • Owkin
  • Paige.AI
  • Path AI
  • Pathos
  • Pfizer
  • Qureight
  • Rad AI
  • Rein Therapeutics
  • Roche
  • Sanofi
  • Servier
  • Snowflake
  • Takeda
  • Tempus
  • Tenacia Biotechnology
  • Tevogen Bio
  • Therasid Bioscience
  • Valo Health
  • Variational AI

Partial List of Participating Experts:

  • Director of AI Capability, AstraZeneca, Spain (own personal views)
  • CEO, Insilico Medicine, US
  • Digital, Strategy and Innovation Director, The Stem, US
  • Vice Chairman and founding CEO, ConcertAI, US
  • former Head of UK/EU Clinical Research at Spectral MD, UK
  • CEO, LucidQuest, UK

Methodology:

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.